Experienced in Chronic T-Cell Leukemia (CTCL)

Dr. David B. Miklos

Hematology | Hematology Oncology | Oncology
300 Pasteur Dr, 
Stanford, CA 
Offers Telehealth
Experienced in Chronic T-Cell Leukemia (CTCL)
300 Pasteur Dr, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Miklos is a Hematologist and a Hematologist Oncology provider in Stanford, California. Dr. Miklos is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 138 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Stanford Health Care
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Santa Clara Family Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
Enrollment Status: Completed
Publish Date: August 29, 2025
Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Biological, Procedure
Study Drugs: Purified T Cells, Purified Regulatory T Cells
Study Phase: Phase 1/Phase 2
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Fludarabine, Cyclophosphamide, CD22 CAR
Study Phase: Phase 1
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate
Study Phase: Phase 1
Pilot Study of [18F]F-AraG PET Imaging to Evaluate Immunological Response to Chimeric Antigen Receptor (CAR) T Cell Therapy in Lymphoma
Pilot Study of [18F]F-AraG PET Imaging to Evaluate Immunological Response to Chimeric Antigen Receptor (CAR) T Cell Therapy in Lymphoma
Enrollment Status: Terminated
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drug: [18F]F-AraG PET
Study Phase: Phase 1
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Biological
Study Drugs: Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders, Cyclophosphamide, Fludarabine
Study Phase: Phase 3
Bone Marrow Grafting for Leukemia and Lymphoma
Bone Marrow Grafting for Leukemia and Lymphoma
Enrollment Status: Enrolling_by_invitation
Publish Date: December 18, 2024
Intervention Type: Procedure
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Biological, Drug
Study Drugs: Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab
Study Phase: Phase 1
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Anti-Thymocyte Globulin, Cyclosporine
Study Phase: Phase 2
A Phase Ib, Multicenter Study to Determine the Safety and Tolerability of Tisagenlecleucel in Combination With Ibrutinib in Adult Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma
A Phase Ib, Multicenter Study to Determine the Safety and Tolerability of Tisagenlecleucel in Combination With Ibrutinib in Adult Patients With Relapsed and/or Refractory Diffuse Large B-cell Lymphoma
Enrollment Status: Terminated
Publish Date: January 31, 2023
Intervention Type: Biological, Drug
Study Drugs: Tisagenlecleucel, Ibrutinib
Study Phase: Phase 1
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Enrollment Status: Completed
Publish Date: January 31, 2023
Intervention Type: Drug, Genetic
Study Drugs: Fludarabine, Cyclophosphamide, Anti-CD20 CAR-T Cells
Study Phase: Phase 1/Phase 2
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
Enrollment Status: Completed
Publish Date: April 15, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

138 Total Publications

NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell Lymphoma.
NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell Lymphoma.
Journal: Blood advances
Published: March 14, 2025
Similar Doctors
Distinguished in Chronic T-Cell Leukemia (CTCL)
Dr. Wei Ding
Hematology | Oncology
Distinguished in Chronic T-Cell Leukemia (CTCL)
Dr. Wei Ding
Hematology | Oncology
300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances

Wei Ding is a Hematologist and an Oncologist in Stanford, California. Dr. Ding is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Prolymphocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Michael S. Khodadoust
Oncology | Hematology | Hematology Oncology
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Michael S. Khodadoust
Oncology | Hematology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Khodadoust is an Oncologist and a Hematologist in Stanford, California. Dr. Khodadoust is rated as an Elite provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are T-Cell Lymphoma, Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Thomas P. Bradley
Hematology Oncology | Oncology | Hematology
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Thomas P. Bradley
Hematology Oncology | Oncology | Hematology
24571 Silver Cloud Ct, 
Monterery, CA 
 (62.1 miles away)
831-373-1719
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Bradley is a Hematologist Oncology specialist and an Oncologist in Monterery, California. Dr. Bradley is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Non-Hodgkin Lymphoma, Anemia, Inflammatory Breast Cancer, Endoscopy, and Laminectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Miklos's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 24 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile